Table 3.
Clinical trials of chimeric antigen receptor T-cell therapy for B-cell lymphoma
| NCT Numberb | Conditionso | Interventiont | P Phase h | Number | Dose D | Outcomes O |
|---|---|---|---|---|---|---|
| NCT04169932 | R/R B-cell lymphoma; NHL | CD20 CAR-T | Early phase I | 20 | (1, 2, 4, 8) × 10^6 cells/kg | NR |
| NCT03994913 | R/R B-NHL | CD19 CAR-T |
Phase I Phase II |
78 | NR | NR |
| NCT04036019 | B-cell lymphoma | CD20 CAR- T | Phase I | 12 | NR | NR |
| NCT04429438 | B-cell lymphoma | 4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 |
Phase I Phase II |
11 | NR | NR |
| NCT04381741 | DLBCL | CD19 CAR-T plus PD1 monoclonal antibody | Phase I | 24 |
(1, 2, 3)× 10^6 cells/kg plus 200 mg Tislelizumab every 3 weeks for 6 times |
NR |
| NCT04260932 | B-cell lymphoma | CD19/CD20 Dual- CAR-T | Phase I | 12 | Escalated dose of (1–6) × 10^6 cells/kg | NR |
| NCT03929107 | B-cell lymphoma | IL-7 and chemokine ligand 19-expressing CD19-CAR-T cells | Phase II | 80 | NR | NR |
| NCT03854994 | B-cell lymphoma; B-ALL | CD19 CAR-T Cells | Phase I | 10 | (1–5) × 10^6 cells/kg | NR |
| NCT04316624 | DLBCL | C-CAR066 | Phase I | 10 |
Low: (1.0–3.0) × 10^6 cells/kg; Medium: (3.0–6.0) × 10^6 cells/kg; High: (6.0–9.0) × 10^6 cells/kg |
NR |
| NCT04240808 | NHL | UCD19 CAR T Cells | Phase I | 20 | NR | NR |
| NCT04539444 | R/R NHL | CD19/22 CART | Phase II | 20 | 3-day split-dose regimen at dose of (0.5–2) × 10^6 cells/kg | NR |
| NCT03881761 | B-cell lymphoma | CD19/CD20 bispecific CAR-T | Phase I | 50 | (1–3) × 10^6 cells/kg | NR |
| NCT04486872 | DLBCL | Autologous humanized CD19/CD20 bispecific CAR-T | Phase I | 18 | 1.00 × 10^6 cells/kg, 3.00 × 10^6 cells/kg or 5.00 × 10^6 cells/kg | NR |
| NCT04257578 | B-NHL; DLBCL; High grade B-cell lymphoma; PMBCL; tFL | Axicabtagene Ciloleucel |
Phase I Phase II |
20 | NR | NR |
| NCT03391726 | B-cell lymphoma | CD19 CAR-T | Phase II | 20 | NR | NR |
| NCT04416984 | B-cell lymphoma | ALLO-647 |
Phase I Phase II |
120 | NR | NR |
| NCT03103971 | B-ALL; DLBCL; PMBL; R/R B-NHL | CD19 CAR-T | Phase I | 73 | NR | NR |
| NCT03287817 |
DLBCL; R/R DLBCL |
AUTO3 |
Phase I Phase II |
171 | (50–900) × 10^6 cells | NR |
| NCT04049513 | B-NHL; DLBCL; PMBCL; tFL; FL; MCL | WZTL002–1 | Phase I | 12 | Starting dose of 5 × 10^4 cells/kg | NR |
| NCT04432506 | R/R DLBCL; R/R high grade B-cell lymphoma; R/R PMBCL; R/R tFL | Axicabtagene Ciloleucel | Phase I | 20 | NR | NR |
| NCT04532268 | ALL; B-NHL | Humanized CD19 CAR-T cells | Early phase I | 72 | NR | NR |
| NCT03932955 | Lymphoma | MC-19PD1 CAR-T cells | Phase I | 15 | NR | NR |
| NCT04191941 | B-NHL; B-ALL; MM | Novel CAR-T | Phase I | 9 | NR | NR |
| NCT04007029 | CLL; R/R DLBCL; FL; MCL; PMBCL; SLL | CAR-T | Phase I | 24 | NR | NR |
| NCT04163302 | B-cell lymphoma | CD19-PD1-CAR-T Cell | Phase II | 30 | NR | NR |
| NCT04215016 | R/R DLBCL Patients With Either CD19 or CD20 Positive | Autologous humanized CD19/CD20 bispecific CAR-T | Phase I | 18 | The first dose is 1.0 × 10^6 cells/kg, the second dose is 3.0 × 10^6 cells/kg and the third dose is 8.0 × 10^6/kg. | NR |
| NCT03664635 | R/R B-NHL | MB-CART20.1 |
Phase I Phase II |
19 |
Safety dose level: 1 × 10^5 cells/kg; Dose level 1: 1 × 10^6 cells/kg; Dose level 2: 3 × 10^6 cells/kg. |
NR |
| NCT04088890 | B-ALL; B-NHL; DLBCL | CD22 CAR-T | Phase I | 95 | ALL: 3 × 10^5 cells/kg(±20%); B-NHL: 1 × 10^6 cells/kg, 3 × 10^6 cells/kg and 1 × 10^7 cells/kg | NR |
| NCT03366324 |
ALL; B-cell lymphoma |
Second generation CAR-T cells |
Phase I Phase II |
20 | NR | NR |
| NCT03277729 | R/R B-NHL; CLL; R/R DLBCL; Recurrent FL; Recurrent MCL; Recurrent MZL | CAR-T |
Phase I Phase II |
30 | NR | NR |
| NCT04532281 | ALL; NHL | CD19 CAR-T | Early phase I | 120 | NR | NR |
| NCT03398967 | B-cell lymphoma | Dual specificity CD19 and CD20 or CD22 CAR-T Cells |
Phase I Phase II |
80 | NR | NR |
| NCT02965092 |
ALL; B-cell lymphoma |
Second generation CAR-T cells |
Phase I Phase II |
80 | (0.89–4.01) × 10^6 CAR-T cells/kg | Median overall survival (OS) was 16.1 months. The 6-month and 12-month OS rates were 69.727 and 64.028%. |
| NCT02963038 | B-cell lymphoma | Autologous CD19- targeting CAR T |
Phase I Phase II |
10 | NR | NR |
| NCT03383952 | B-cell lymphoma | ICAR19 CAR-T cells | Phase I | 20 | NR | NR |
| NCT04007978 | B-cell lymphoma; ALL | Third generation CAR- T | Phase I | 50 | NR | NR |
| NCT04532203 | ALL; NHL | CAR-T cells | Early phase I | 72 | NR | NR |
| NCT04603872 | R/R MM; R/R ALL; R/R NHL | CD19/BCMA CAR T-cells | Early phase I | 120 | NR | NR |
| NCT03939026 | R/R Large B-Cell Lymphoma; R/R FL | ALLO-647 | Phase I | 54 | NR | NR |
| NCT04008251 |
ALL; B-cell lymphoma |
Second generation humanized CAR-T | Phase I | 10 | NR | NR |
| NCT03118180 | Lymphoma | CD19 CAR-T |
Phase I Phase II |
50 | NR | NR |
| NCT02650414 | B-cell lymphoma | CD22 CAR-T | Phase I | 15 |
Subjects < 50 kg: (0.2–1) × 10^7 cells/kg Subjects > 50 kg: (1–5) × 10^8 cells |
NR |
| NCT04317885 | B-NHL | CD19/CD20-directed CAR-T cells | Phase I | 25 | NR | NR |
| NCT03166878 | B-cell lymphoma | UCART019 |
Phase I Phase II |
80 | Day 0: 10% of total dose. Day 1: 30% of total dose if patient is stable. Day 2: 60% of total dose if patient is stable. | NR |
| NCT03720457 | DLBCL; FL | CD19 CAR-T | Phase I | 18 | NR | NR |
| NCT03559439 | B-cell lymphoma; B-ALL | CD19 CAR T | Phase I | 9 | Low: 1 × 10^5 cells/kg; Medium: 2 × 10^6 cells/kg; High: 6 × 10^6 cells/kg | NR |
| NCT04088864 | B-cell lymphoma; ALL | Autologous CD22 CAR T | Phase I | 52 |
R/R B-ALL: 1 × 10^6 cells/kg (±20%). Lymphoma: 1 × 10^6 cells/kg (±20%). |
NR |
| NCT03696784 | B-cell lymphoma | iC9-CAR19 T cells | Phase I | 30 | (1–2) × 10^6 cells/kg | NR |
| NCT04204161 |
R/R ALL; B-cell lymphoma |
CAR-T19/CAR-T22 | Phase I | 30 | The recommand dose: 1 × 10^5/kg-2.5 × 10^8/kg | NR |
| NCT03853616 |
ALL; B-cell lymphoma; R/R CLL |
MB-CART19.1 |
Phase I Phase II |
48 | 1 × 10^5/kg-3 × 10^6/kg | NR |
| NCT03881774 | B-cell lymphoma | CAR-T cells | Phase I | 20 | (0.5–3) × 10^6/kg | NR |
| NCT04176913 | DLBCL; FL; MCL; SLL | LUCAR-20S CAR-T cells | Phase I | 41 | NR | NR |
| NCT04156243 | B-cell lymphoma | CD19 CAR T cells | Early phase I | 20 | NR | NR |
| NCT04089215 | NHL; DLBCL; FL | CD19 CAR-T | Phase II | 82 | 1.0 × 10^8 and 1.5 × 10^8 cells | Three month ORR: 60.3% |
| NCT04205838 | DLBCL; High grade B-cell lymphoma; R/R tFL; R/R PMBCL | Axicabtagene Ciloleucel | Phase II | 36 | NR | NR |
| NCT04464200 |
DLBCL; PMBCL; tFL; CLL; MZL; WM; Burkitt’s lymphoma; Primary CNS lymphoma |
19(T2)28z1xx CAR T cells | Phase I | 60 |
Planned flat-dose levels: (25, 50, 100, 150, 200) × 10^6 cells; De-escalation dose: 12.5 × 10^6 cells. |
NR |
| NCT04545762 |
Refractory NHL; Burkitt lymphoma; MCL; FL; PMBCL; DLBCL; SLL |
CD19 CAR-T cells | Phase I | 36 | Starting dose: 5 × 10^5 cells/kg | NR |
| NCT03999697 | DLBCL; FL; MCL; Plasma cell neoplasm | CD22 CAR-T | Phase I | 10 | NR | NR |
| NCT04214886 |
B-ALL; B-cell lymphoma |
CD19-CD34 CAR-T | Phase I | 24 | 1 × 10^6 cells/kg (± 20%) to 2 × 10^6 cells/kg | NR |
| NCT03666000 | NHL; B-ALL | PBCAR0191 |
Phase I Phase II |
92 |
Starting dose: 3 × 10^5 cells/kg; Subsequent dose groups: escalating doses to a maximum dose of 9 × 10^6 cells/kg. |
NR |
| NCT02772198 | B-ALL; B-NHL | CD19 CAR T cells |
Phase I Phase II |
300 | NR | ORR was 84% (30/36) in ALL and 62% (32/52) in NHL. |
| NCT04156178 | B-cell lymphoma | CD20-CD19 CAR-T | Early phase I | 12 | NR | NR |
| NCT03743246 | Precursor cell lymphoblastic leukemia- lymphoma; B-cell lymphoma | JCAR017 |
Phase I Phase II |
121 | 0.05 × 10^6–0.75 × 10^6 cells/kg | NR |
| NCT03676504 | ALL; CLL; DLBCL; FL; MCL | CD19 CAR T Cells |
Phase I Phase II |
48 | 1 × 10^6 cells/m^2 to 20 × 10^7 cells/m^2 | NR |
| NCT03448393 |
ALL; B-cell lymphoma; B-NHL |
CD19/CD22 CAR T- Cells | Phase I | 89 | 1 × 10^5 cells/kg (+/− 20%); 3 × 10^5 cells/kg (+/− 20%); 1 × 10^6 cells/kg; 3 × 10^6 cells/kg (+/− 20%); 1 × 10^7 cells/kg (+/− 20%). | NR |
| NCT04186520 | B-NHL; MCL | CAR-T |
Phase I Phase II |
32 | 2.5 × 10^6 cells/kg | NR |
| NCT02631044 | NHL; DLBCL; FL; MCL; PMBCL | JCAR017 | Phase I | 314 | 50 × 10 CAR-T cells [one or two doses], 100 × 10 CAR-T cells, and 150 × 10 CAR-T cells. | ORR was 73% and CR rate was 53% among 256 patients with B-NHL. |
| NCT03744676 |
B-NHL; B-cell lymphoma; DLBCL |
lisocabtagene maraleucel | Phase II | 80 | NR | NR |
| NCT02706405 | DLBCL; PMBCL | JCAR014 | Phase I | 42 | NR | NR |
| NCT04226989 | ALL; NHL | CT-RD06 | Early phase I | 72 | NR | NR |
| NCT04314843 | B-cell lymphoma | Axicabtagene Ciloleucel |
Phase I Phase II |
36 | NR | NR |
| NCT03497533 | B-NHL | TriCAR-T-CD19 |
Phase I Phase II |
6 | (0.5–1) × 10^6 CAR-T cells/kg | NR |
| NCT03720496 | B-NHL | CD19-TriCAR-T | Phase I | 6 | (0.1–1) × 10^6 cells/kg | NR |
| NCT03105336 | FL; MZL; Indolent NHL | Axicabtagene ciloleucel | Phase II | 160 | NR | NR |
| NCT03310619 | NHL; DLBCL; FL | JCAR017 |
Phase I Phase II |
75 | 50 × 10^6 CAR-T cells; 100 × 10^6 CAR-T cells. | NR |
Abbreviations: CAR chimeric antigen receptor, ORR objective response rate, CR complete response, DLBCL diffuse large B-cell lymphoma, B-ALL B-cell acute lymphoblastic leukemia, NHL non-Hodgkin lymphoma, B-NHL B-cell non-Hodgkin lymphoma, R/R B-NHL refractory/relapsed B-cell non-Hodgkin lymphoma, PMBCL primary mediastinal large B-cell lymphoma, FL follicular lymphoma, tFL transformed follicular lymphoma, R/R tFL refractory/relapsed transformed follicular lymphoma, MCL mantle cell lymphoma, MM multiple myeloma, SLL small lymphocytic lymphoma, CLL chronic lymphocytic leukemia, MZL marginal zone lymphoma, WM Waldenstrom macroglobulinemia